SOURCE: Cleveland BioLabs, Inc.

May 14, 2008 09:47 ET

Cleveland BioLabs to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference

BUFFALO, NY--(Marketwire - May 14, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI), today announced that the Company is scheduled to present at the Rodman & Renshaw 5th Annual Global Healthcare Conference, on May 19-20, in Monte Carlo.

Michael Fonstein, Ph.D., Chief Executive Officer and President of Cleveland BioLabs, will give a presentation followed by a question and answer session on May 19, at 10:00 a.m. Central European Summer Time. The presentation webcast may be accessed at the Company's website, www.cbiolabs.com under investor information, or at http://www.wsw.com/webcast/rrshq13/cbli.

A replay of the presentation will be archived for 90 days after the conference at the same locations. For more information about the Rodman & Renshaw 5th Annual Global Healthcare Conference, please visit Rodman & Renshaw's website at www.rodmanandrenshaw.com.

Cleveland BioLabs is developing a pipeline of products from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation and chemotherapy. Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer agents.

The Company recently announced completion of enrollment for its ongoing Phase II clinical trial of Curaxin CBLC102 in advanced, hormone-refractory (androgen independent) prostate cancer. CBLC102 is an orally administered, small molecule designed to kill tumor cells through multiple mechanisms of action targeting signaling pathways frequently deregulated in cancer.

The Company received a contract from the Department of Defense valued at up to $8.9 million for the advanced development of Protectan CBLB502 as a medical radiation countermeasure to treat radiation injury following exposure to radiation from nuclear or radiological weapons. Protectan CBLB502 is undergoing expedited approval for biodefense use through the FDA's two-animal rule requiring efficacy in animals and safety testing in a representative sample of healthy human volunteers. Protectan CBLB502 has demonstrated animal efficacy and is expected to start human safety studies in 2008. A Phase I/II medical trial for Protectan CBLB502 in head and neck cancer patients for reduction of radiation and chemotherapy toxicities is also expected to start later in 2008.

Science Magazine published a breakthrough peer-reviewed paper on Protectan CBLB502's radioprotective capabilities in the April 11, 2008 issue. The paper demonstrated the success of Cleveland BioLabs's principle proprietary approach to protection of healthy tissue from a variety of potentially lethal cellular stresses and underscored Protectan CBLB502's potential as a radioprotector in both defense and medical settings.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Rachel Levine
    Director Corporate Development & Communications
    Cleveland BioLabs, Inc.
    T: (646) 284-9439
    E: rlevine@cbiolabs.com